Fortnightly review: Polymyalgia rheumatica and temporal arteritis: Diagnosis and management

BMJ

Volumn 314, Issue 7090, 1997, Pages 1329-

  Swannell, A J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; STEROID;

ADULT; AGED; CLINICAL FEATURE; DRUG MEGADOSE; HUMAN; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; SHORT SURVEY; SIDE EFFECT; TEMPORAL ARTERITIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; POLYMYALGIA RHEUMATICA; TEMPORAL ARTERITIS;

EID: 0030966076     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.314.7090.1329     Document Type: Article

References (33)

1. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica in a Danish county. Arthritis Rheum 1987; 30: 294#9.
2. Dixon A St J, Beardwell A, Kay A, Wanka J, Wong YT. Polymyalgia and temporal arteritis. Ann Rheum Dis 1966; 25: 203#8.
3. Healey A. Relation of giant cell arteritis to polymyalgia rheumatica. In: Hazleman BL, Bengtsson B-A, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991: 372#3.
4. Bengtsson B-A. Epidemiology of giant cell arteritis. In: Hazleman BL, Bengtsson B-A, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991: 380#3.
5. Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12 year epidemiological study. Br J Rheumatol 1994; 33: 938#41.
6. Salvarini C, Macchioni P, Zizzi F, Mantovani W, Rossi F, Castri G, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 3: 351#6.
7. Bengtsson B-A, Malmvall B-E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis Rheum 1981; 24: 899#904.
8. Calamia KT, Hunder GG. Clinical manifestations of giant cell arteritis. In: Alarcon-Segovia D, ed. Clinics in the rheumatic diseases. London: W B Saunders, 1980:391.
9. Jones JG. Clinical features of giant cell arteritis. In: Hazleman BL, Bengtsson B-A, eds. Baillière's. clinical rheumatology. London: Baillière Tindall, 1991:414.
10. Hollenhorst RW, Brown JR, Wagener HP, Schick RM. Neurologic manifestations of temporal arteritis. Neurology 1960; 10: 490#8.
11. Achkar AA, Lie JT, Gabriel SE, Hunder GG. Giant cell arteritis involving the facial artery. J Rheumatol 1995; 22: 360#2.
12. Patterson A, Scully C, Barnard N, Griffith MJ, Eveson JW, Novelli M. Necrosis of the tongue in a patient with intestinal infarction. Oral Surg Oral Med Oral Pathol 1992; 74: 582#6.
13. Sadler NA, Ziccardi V, Ochs M. Differential diagnosis of jaw pain in the elderly. J Am Dent Assoc 1995; 126: 1263#72.
14. Hayreh SS. Ophthalmic features of giant cell arteritis. In: Hazleman BL, Bengtsson B-A, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991: 434#6.
15. Sandercock PAG, Warlow CP, Jones LN, Starkey IR. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 1989; 298: 75#80.
16. Paulley JW. Coronary ischaemia and occlusion in giant cell (temporal) arteritis. Acta Med Scand 1980; 208: 257#63.
17. Evans JM, Bowles CA, Bjornsson J, Mullaly CJ, Hunder GG. Thoracic aortic aneurysm and rupture in giant cell arteritis. Arthritis Rheum 1994; 37: 1539#47.
18. Kyle V. Laboratory investigations including liver in polymyalgia rheumatica/giant cell arteritis. In: Hazleman BL, Bengtsson B-A, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991:476.
19. Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168#70.
20. Anderson R. Immunological studies in giant cell arteritis. In: Hazleman BL, Bengtsson BA, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991:409.
21. Al-Hussaini AS, Swannell AJ. Peripheral joint involvement in polymyalgia rheumatica: a clinical study of 56 cases. Br J Rheumatol 1985; 24: 27#30.
22. Hazleman BL. Polymyalgia rheumatica and giant cell arteritis. In: Butler R, Jayson M, Moll J, Isenberg D, eds. Practical problems. Reports on the rheumatic diseases. Chesterfield: Arthritis and Rheumatism Council, 1992.
23. Chakravarty K, Elgabani HS, Scott DGI, Merry P. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994; 33: 152#6.
24. Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis 1984; 43: 416.
25. Cullen JF. Temporal arteritis. Br J Ophthalmol 1972; 56: 584#8.
26. Kyle V. Treatment of polymyalgia rheumatica/giant cell arteritis. In: Hazleman BL, Bengtsson B-A, eds. Baillière's clinical rheumatology. London: Baillière Tindall, 1991:486.
27. Chuang T-Y, Hunder GG, Ilstrupp DM, Kurland LT. Polymyalgia rheumatica: a 10 year epidemiological and clinical study. Ann Intern Med 1982; 97: 190#212.
28. Hosie G, Kirwan J. The diagnosis and treatment of polymyalgia rheumatica in general practice. Musculoskel Med 1995; 2: 10#1.
29. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374#8.
30. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15 year survey of 43 patients. J Rheumatol 1994; 21: 1283#6.
31. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33: 348#50.
32. Hernandez-Garcia C, Soriano C, Marodo C, Ramos P, Ferrandez-Gutierrez B, Herrero M, et al. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol 1994; 23: 295#8.
33. Nesher G, Sonnenblick M. Steroid sparing medications in temporal arteritis–report of three cases and review of 174 reported patients. Clin Rheumatol 1994; 13: 289#92.